Endpoints News 生物医药· ENDPOINTS·· 2026-10-14AI 评分28
Ultragenyx 完成第二笔 PRV 交易;Biomea 口服 GLP-1 数据致股价大跌
Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slump
AI 导读
Ultragenyx Pharmaceutical 本月出售第二笔 PRV,该公司为商业化阶段的罕见病制药企业。Biomea 口服 GLP-1 数据公布后股价大幅
正文
Plus news about Sanofi, Pharming, Skyhook Bio and Altay Therapeutics.
Ultragenyx Pharmaceutical sells second PRV this month: The commercial-stage rare disease drugmaker sold its second …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news